A race has broken out on the atopic eczema market in the US. While Danish pharmaceutical firm Leo Pharma leads among three new contenders, having had its candidate approved by the US Food and Drug Administration (FDA) around New Year's, it will soon be followed by two other treatments.
The FDA has just approved therapies from two large US-based companies, Abbvie and Pfizer, for patients aged 12 and up with moderate-to-severe atopic eczema, also known as atopic dermatitis. A total of three firms are thus ready to fight it out for market shares of the enormous disease area, where only one biologic drug, French Sanofi's Dupixent, has been available until now.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
WS Audiology brings in head of EMEA region from Coloplast
The hearing aid manufacturer has appointed Coloplast’s now outgoing president for emerging markets as president for the EMEA region.
Dupixent could dominate pediatric eczema market for up to a decade, analysis finds
Sanofi and Regeneron will be able to call themselves market leaders within atopic eczema treatment for children aged 6 months to 5 for years to come, according to Globaldata.
FDA advisors support approval for Ferring's intestinal infection medicine
All signs indicate that Ferring Pharmaceuticals is on the cusp of being market authorized for its biologic candidate against C. difficile infection.
Pharmacosmos expects massive growth in four years
The company’s new chief executive has ambitions of reaching a DKK 2.5bn (USD 325m) revenue within the time frame.
The Lundbeck Foundation, ATP, LEGO asset manager join forces on secretive project
Three of Denmark’s biggest funds have come together for a yet unknown project, which includes the establishment of three new firms.
Product specialist in Cardio Rhythm Management, Zealand 
Experienced IT Business Solutions Manager for the Danish Medicines Agency 
Calibration Technician 
Manager of QA, BHS Logistics 
Senior Drug Product Specialist 
Senior Manager, System Change & Release Management 
Nordic Key Account Manager, Hollister & Dansac 
Pharmacovigilance & Regulatory Assistant with an interest in non-fiction 
Clinical Project Lead 
Chief Business Officer 
Vice President, Medical Affairs 
Product specialist 
Senior CMC Regulatory Manager 
KLIFO is looking for a Compliance Coordinator for our Glostrup office